6MW3511 in Patients With Advanced Solid Tumor

Summary

This is a phase I/II , open-label, multicenter single arm study designed to evaluate the safety, tolerability, pharmacokinetic (PK), and immunogenicity of 6MW3511.

Timeline

Start

2022-10

Primary completion

2024-06

Completion

2024-09

Drugs

Indications